# Tafamidis (Vyndaqel)

Source: https://ourhealthnetwork.com/drugs/tafamidis
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Tafamidis?

Tafamidis (brand name: Vyndaqel) is a transthyretin stabilizer. It is prescribed to treat treat transthyretin amyloid cardiomyopathy (attr-cm; a condition in which a protein (transthyretin) builds up in the wall of the heart making it thicker which makes it difficult for the heart to pump blood adequately). Across the United States, 1,000 doctors prescribe Tafamidis to approximately 3,000 Medicare patients.

## Brand names

Vyndaqel

## Indications

Tafamidis is primarily prescribed for the treatment of treat transthyretin amyloid cardiomyopathy (attr-cm; a condition in which a protein (transthyretin) builds up in the wall of the heart making it thicker which makes it difficult for the heart to pump blood adequately).

## Conditions treated

- [Transthyretin Amyloid Cardiomyopathy](https://ourhealthnetwork.com/conditions/transthyretin-amyloid-cardiomyopathy)
- [Cardiomyopathies](https://ourhealthnetwork.com/conditions/cardiomyopathies)

## Mechanism of action

Tafamidis is a selective stabilizer of TTR. Tafamidis binds to TTR at the thyroxine binding sites, stabilizing the tetramer and slowing dissociation into monomers, the rate-limiting step in the amyloidogenic process.

## Drug classification

- Established Pharmacologic Class: transthyretin stabilizers
- Route of administration: ORAL

## Common side effects

Contact your doctor or pharmacist for complete side effect information for this medication

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)